



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

Box 8/1635

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900

GSHISHIMA@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3081

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

November 1, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Box Sequence, P. O. Box 2327, Arlington, VA 22202, on the date below:	
November 1, 2002 Date	 Gina N. Shishima

BOX SEQUENCE
Commissioner for Patents
Washington, DC 20231

Re: SN 09/660,568 entitled "DIAGNOSIS OF DISEASE STATE USING MRNA
PROFILES IN PERIPHERAL LEUKOCYTES" by Ralph et al.
Our ref: UROC:014USD1/10023400

Commissioner:

Enclosed for filing in the above-referenced patent application are:

- (1) Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence Disclosures;
- (2) Statement as Required Under 37 C.F.R. §1.85(a) and (b) and as Required Under 37 C.F.R. §1.821(g) (with paper copy and computer readable copy of sequence listing); and
- (3) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/UROC:014USD1.

Respectfully submitted,

Gina N. Shishima
Reg. No. 45,104

:lb
Encl.: As stated

25227563.1